Dr. Derek Lewis, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 186
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
AR license C6631
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center-Little Rock Little Rock, AR
- Chi-St Vincent Infirmary Little Rock, AR
Medical groups
- North Little Rock Primary Care and Diagnostic Clinic PLLC (2 clinicians)
- Arkansas Primary Care Clinics PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 186
- Services billed
- 1,792
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 464 | 137 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 279 | 34 |
| Advance care planning, first 30 minutes | 111 | 109 |
| Annual alcohol misuse screening, 5 to 15 minutes | 110 | 110 |
| Annual depression screening, 5 to 15 minutes | 102 | 102 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 97 | 97 |
| Telephone medical discussion with physician, 11-20 minutes | 90 | 61 |
| Blood glucose (sugar) test performed by hand-held instrument | 89 | 46 |
| Hospital discharge day management, 30 minutes or less | 68 | 38 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 54 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 21 payments worth $858 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $535 |
|---|---|
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $137 |
| Biotronik Inc. | $67.67 |
| AbbVie Inc. | $26.59 |
| Dexcom, Inc. | $17.96 |
| Lilly USA, LLC | $17.20 |
| AstraZeneca Pharmaceuticals LP | $14.72 |
| Kowa Pharmaceuticals America, Inc. | $14.38 |
| Food and Beverage | $608 |
|---|---|
| Travel and Lodging | $251 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $251 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $447,526 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.